pd 98059 has been researched along with Cancer of Ovary in 41 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND Ovarian cancer commonly presents at a late stage and is associated with poor prognosis." | 1.51 | Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro. ( Ding, X; Liu, W; Tian, X; Zhang, L, 2019) |
| "The cell viabilities of ovarian cancer cell line SKOV-3 and SKOV-3/DDP were detected using MTT assay." | 1.46 | PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process. ( Chen, J; Gao, X; Hou, L; Hou, X; Li, Z; Mu, H; Wang, L; Xin, B, 2017) |
| "Obesity is known to be an important risk factor for many types of cancer, such as breast, prostate, liver and endometrial cancer." | 1.39 | Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. ( Breslin, M; Chang, YC; Chen, C; Lan, MS, 2013) |
| "In high-grade ovarian cancer cultures, it has been shown that epidermal growth factor (EGF) induces cell invasion by activating an epithelial-mesenchymal transition (EMT)." | 1.38 | EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? ( Auersperg, N; Cheng, JC; Leung, PC, 2012) |
| "We treated 7 ovarian cancer cell lines with CDDP alone or with CDDP and either a PI3K inhibitor (LY294002), a MEK inhibitor (PD98059), or a MEK/ERK activator (phorbol 12-myristate 13-acetate [PMA]) and assessed cell viability, expression of MEK/ERK and PI3K/Akt, cell cycle distribution, and apoptosis." | 1.38 | Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. ( Harada, T; Itamochi, H; Kawaguchi, W; Kigawa, J; Kudoh, A; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K, 2012) |
| "ClC plays an important role in ovarian cancer cell migration." | 1.37 | Effect of a chloride channel inhibitor, 5-nitro-2-(3-phenylpropylamino)-benzoate, on ovarian cancer cell migration. ( Gao, J; Li, S; Yu, Z; Zhang, ZX, 2011) |
| "Verapamil was also inhibitory, indicating that gonadotropins activate calcium influx via L-type voltage-dependent calcium channels." | 1.36 | Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. ( Baxter, RC; Bolitho, C; Marsh, DJ; Mertens-Walker, I, 2010) |
| "Human ovarian cancer cell line SKOV3 was incubated with different concentrations of MG262 for 24 and 48 hours." | 1.35 | [Effect of extracellular signal regulated kinase signal pathway on apoptosis induced by MG262 in ovarian cancer cells]. ( Cui, BX; Jiang, J; Kong, BH; Li, P; Qu, X; Song, K; Wang, WX; Yang, XS; Zhang, YZ, 2008) |
| "OVCAR3 ovarian cancer cells express three sphingosine 1-phosphate (S1P) receptors, S1P(1), S1P(2), and S1P(3), but not S1P(4)." | 1.34 | S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells. ( Bae, YS; Kim, JM; Kim, MK; Kim, SD; Lee, HY; Lee, SY; Park, KS; Ryu, SH, 2007) |
| "To investigate the role of FSH in ovarian cancer development, the present study examined the expression of FSH receptor (FSH-R) and the effect of FSH on proliferation of normal, preneoplastic, and neoplastic ovarian surface epithelium (OSE) cells." | 1.31 | Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. ( Auersperg, N; Choi, KC; Kang, SK; Leung, PC; Tai, CJ, 2002) |
| "Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis." | 1.30 | Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. ( Cui, W; Pelling, JC; Persons, DL; Yazlovitskaya, EM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 24 (58.54) | 29.6817 |
| 2010's | 14 (34.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Tian, X | 1 |
| Ding, X | 1 |
| Zhang, L | 1 |
| Ghasemi, A | 1 |
| Hashemy, SI | 1 |
| Aghaei, M | 1 |
| Panjehpour, M | 1 |
| Hou, L | 1 |
| Hou, X | 1 |
| Wang, L | 1 |
| Li, Z | 1 |
| Xin, B | 1 |
| Chen, J | 1 |
| Gao, X | 1 |
| Mu, H | 1 |
| Muniyan, S | 1 |
| Chou, YW | 1 |
| Tsai, TJ | 1 |
| Thomes, P | 1 |
| Veeramani, S | 1 |
| Benigno, BB | 1 |
| Walker, LD | 1 |
| McDonald, JF | 1 |
| Khan, SA | 1 |
| Lin, FF | 1 |
| Lele, SM | 1 |
| Lin, MF | 1 |
| Huang, X | 1 |
| Jin, J | 1 |
| Shen, S | 1 |
| Xia, Y | 1 |
| Xu, P | 1 |
| Zou, X | 1 |
| Wang, H | 1 |
| Yi, L | 1 |
| Wang, Y | 2 |
| Gao, Q | 1 |
| Park, SH | 1 |
| Kim, KY | 1 |
| An, BS | 1 |
| Choi, JH | 1 |
| Jeung, EB | 1 |
| Leung, PC | 4 |
| Choi, KC | 3 |
| Wang, WX | 1 |
| Kong, BH | 1 |
| Li, P | 1 |
| Song, K | 1 |
| Qu, X | 1 |
| Cui, BX | 1 |
| Jiang, J | 1 |
| Zhang, YZ | 2 |
| Yang, XS | 1 |
| Xu, LL | 1 |
| Mei, JH | 1 |
| Chen, JX | 1 |
| Xu, S | 1 |
| Qin, HY | 1 |
| Wang, SS | 1 |
| Jeong, KJ | 1 |
| Park, SY | 1 |
| Seo, JH | 1 |
| Lee, KB | 1 |
| Choi, WS | 1 |
| Han, JW | 1 |
| Kang, JK | 1 |
| Park, CG | 1 |
| Kim, YK | 1 |
| Lee, HY | 2 |
| Liu, JJ | 1 |
| Lin, B | 2 |
| Hao, YY | 1 |
| Li, FF | 1 |
| Liu, DW | 1 |
| Qi, Y | 1 |
| Zhu, LC | 1 |
| Zhang, SL | 1 |
| Iwamori, M | 2 |
| Mertens-Walker, I | 1 |
| Bolitho, C | 2 |
| Baxter, RC | 2 |
| Marsh, DJ | 2 |
| Hahn, MA | 1 |
| Yu, Z | 1 |
| Zhang, ZX | 1 |
| Li, S | 1 |
| Gao, J | 1 |
| Liu, D | 1 |
| Liu, J | 1 |
| Liu, S | 1 |
| Hou, R | 1 |
| Hao, Y | 1 |
| Liu, Q | 1 |
| Zhang, S | 1 |
| Cheng, JC | 1 |
| Auersperg, N | 3 |
| Li, L | 1 |
| Guo, X | 1 |
| Jin, X | 1 |
| Sun, W | 1 |
| Zhang, X | 1 |
| Xu, RC | 1 |
| Nonaka, M | 1 |
| Itamochi, H | 1 |
| Kawaguchi, W | 1 |
| Kudoh, A | 1 |
| Sato, S | 2 |
| Uegaki, K | 1 |
| Naniwa, J | 1 |
| Shimada, M | 1 |
| Oishi, T | 1 |
| Terakawa, N | 1 |
| Kigawa, J | 1 |
| Harada, T | 1 |
| Chen, C | 1 |
| Chang, YC | 1 |
| Lan, MS | 1 |
| Breslin, M | 1 |
| Kobayashi, H | 3 |
| Suzuki, M | 3 |
| Kanayama, N | 3 |
| Nishida, T | 1 |
| Takigawa, M | 1 |
| Terao, T | 3 |
| Xia, B | 1 |
| Lu, J | 1 |
| Tai, CJ | 2 |
| Tzeng, CR | 1 |
| Denkert, C | 1 |
| Koch, I | 1 |
| Berger, S | 1 |
| Köbel, M | 1 |
| Siegert, A | 1 |
| Hauptmann, S | 1 |
| Mabuchi, S | 1 |
| Ohmichi, M | 2 |
| Kimura, A | 2 |
| Ikebuchi, Y | 1 |
| Hisamoto, K | 1 |
| Arimoto-Ishida, E | 1 |
| Nishio, Y | 1 |
| Takahashi, K | 1 |
| Tasaka, K | 1 |
| Murata, Y | 2 |
| Li, DJ | 1 |
| Huang, W | 1 |
| Meng, FK | 1 |
| Wei, SQ | 1 |
| Sui, LH | 1 |
| Zheng, JH | 1 |
| Zhang, GM | 1 |
| Kao, YL | 1 |
| Zhang, Y | 2 |
| Shang, H | 1 |
| Dong, W | 1 |
| Zhao, Y | 1 |
| Sun, LG | 1 |
| Wakahara, K | 1 |
| Yagyu, T | 1 |
| Matsuzaki, H | 1 |
| Kondo, T | 1 |
| Kurita, N | 1 |
| Sekino, H | 1 |
| Inagaki, K | 1 |
| Spinella, F | 1 |
| Rosanò, L | 1 |
| Elia, G | 1 |
| Di Castro, V | 1 |
| Natali, PG | 1 |
| Bagnato, A | 1 |
| Xing, D | 1 |
| Orsulic, S | 1 |
| Kang, S | 1 |
| Luo, R | 1 |
| Smicun, Y | 1 |
| Fishman, DA | 1 |
| Meng, Y | 1 |
| Coltella, N | 1 |
| Rasola, A | 1 |
| Nano, E | 1 |
| Bardella, C | 1 |
| Fassetta, M | 1 |
| Filigheddu, N | 1 |
| Graziani, A | 1 |
| Comoglio, PM | 1 |
| Di Renzo, MF | 1 |
| Park, KS | 1 |
| Kim, MK | 1 |
| Kim, SD | 1 |
| Lee, SY | 1 |
| Kim, JM | 1 |
| Ryu, SH | 1 |
| Bae, YS | 1 |
| Yazlovitskaya, EM | 3 |
| Pelling, JC | 3 |
| Persons, DL | 3 |
| Cui, W | 2 |
| Hayakawa, J | 1 |
| Kurachi, H | 1 |
| Ikegami, H | 1 |
| Matsuoka, T | 1 |
| Jikihara, H | 1 |
| Mercola, D | 1 |
| Lee, H | 1 |
| Jiang, F | 1 |
| Wang, Q | 1 |
| Nicosia, SV | 1 |
| Yang, J | 1 |
| Su, B | 1 |
| Bai, W | 1 |
| Mayo, MS | 1 |
| Thant, AA | 1 |
| Nawa, A | 1 |
| Kikkawa, F | 1 |
| Ichigotani, Y | 1 |
| Sein, TT | 1 |
| Amin, AR | 1 |
| Hamaguchi, M | 1 |
| Ding, S | 1 |
| Chamberlain, M | 1 |
| McLaren, A | 1 |
| Goh, L | 1 |
| Duncan, I | 1 |
| Wolf, CR | 1 |
| Kang, SK | 1 |
41 other studies available for pd 98059 and Cancer of Ovary
| Article | Year |
|---|---|
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Dual Specificity Phosphatase 2 | 2019 |
Leptin induces matrix metalloproteinase 7 expression to promote ovarian cancer cell invasion by activating ERK and JNK pathways.
Topics: Anthracenes; Cell Line, Tumor; Cell Movement; Female; Flavonoids; Gene Knockdown Techniques; Humans; | 2018 |
PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; C | 2017 |
p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Estrogens; Female; Flavonoids; Humans; Ovarian Neoplasms; Prot | 2015 |
Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line.
Topics: Androstenedione; Aromatase; Cell Line, Tumor; Drug Screening Assays, Antitumor; Estradiol; Female; F | 2016 |
Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38.
Topics: Cell Growth Processes; Endocrine Disruptors; Enzyme Activation; Enzyme Inhibitors; Estrogens; Female | 2009 |
[Effect of extracellular signal regulated kinase signal pathway on apoptosis induced by MG262 in ovarian cancer cells].
Topics: Apoptosis; Boronic Acids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relatio | 2008 |
[Study the role of PD98059 in ovarian carcinoma cell line HO-8910].
Topics: Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma; Cell Cycle; Cell Line; Cell Line, Tumor; En | 2008 |
Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Topics: Butadienes; Cell Line, Tumor; Cell Movement; CSK Tyrosine-Protein Kinase; Cyclooxygenase 2; ErbB Rec | 2008 |
Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p27; ErbB Recepto | 2010 |
Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}.
Topics: Acetophenones; Benzopyrans; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cell Movement; Cell | 2010 |
The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
Topics: Cell Growth Processes; Cell Line, Tumor; Chemokine CXCL1; ErbB Receptors; Female; Flavonoids; Hepari | 2010 |
Effect of a chloride channel inhibitor, 5-nitro-2-(3-phenylpropylamino)-benzoate, on ovarian cancer cell migration.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Cell Line, Tumor; Cell Movement; Chloride Channels; Culture | 2011 |
Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways.
Topics: Antibodies; Cell Line, Tumor; Chromones; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; C | 2012 |
EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Chromones; Cystadenocarcinoma, Serous; Epidermal Growth | 2012 |
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.
Topics: Androstadienes; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Tra | 2012 |
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Chromones; Cisplatin; | 2012 |
Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
Topics: Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Enzyme Activation; Enzyme In | 2013 |
Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade.
Topics: Bone Neoplasms; Butadienes; Carcinoma; Chondrosarcoma; Depression, Chemical; Enzyme Activation; Enzy | 2002 |
[Rapid inhibition of extracellular signal-regulated kinase 1/2 in a human ovarian cancer cell line by dexamethasone].
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; De | 2002 |
Adenosine triphosphate activates mitogen-activated protein kinase in pre-neoplastic and neoplastic ovarian surface epithelial cells.
Topics: Adenosine Triphosphate; Cell Division; DNA-Binding Proteins; Epithelium; ets-Domain Protein Elk-1; F | 2003 |
Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Collagen; Cytokines; Drug Combinations; Enz | 2003 |
Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antioxidants; Apo | 2004 |
[To inhibit ERK for enhancing chemotherapy sensitivity of drug-resistance cell lines of leukemia and ovarian carcinoma].
Topics: Apoptosis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flavonoids; HL-60 Cells; Humans; Le | 2003 |
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Topics: Binding, Competitive; Cell Line, Tumor; Cell Movement; Collagen; Depression, Chemical; Drug Combinat | 2004 |
Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Enzyme | 2004 |
[Effect of mitogen-activated protein kinase antagonist--PD98059 on ovarian neoplastic cell growth].
Topics: Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Female; Flavonoids; Humans; Mitogen-Act | 2004 |
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Topics: DNA-Binding Proteins; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; MAP | 2004 |
Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Endotheli | 2004 |
A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.
Topics: Animals; Apoptosis; Ascites; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Models | 2005 |
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Topics: Animals; Antigen Presentation; Antigens, Surface; Apoptosis; Aspirin; Cell Line, Tumor; Cell Membran | 2006 |
p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tu | 2006 |
S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells.
Topics: Blotting, Western; Calcium; Cell Line, Tumor; Cell Movement; Chemotaxis; Chromones; Enzyme Inhibitor | 2007 |
Association of apoptosis with the inhibition of extracellular signal-regulated protein kinase activity in the tumor necrosis factor alpha-resistant ovarian carcinoma cell line UCI 101.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cell Div | 1999 |
Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Topics: Adenocarcinoma; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cisplatin; Cycl | 1999 |
Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line.
Topics: Antineoplastic Agents; Calcium; Cisplatin; Drug Interactions; Enzyme Activation; Female; Flavonoids; | 1999 |
MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.
Topics: Endometrial Neoplasms; Enzyme Activation; Enzyme Inhibitors; Estrogen Antagonists; Estrogen Receptor | 2000 |
Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, | 2000 |
Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.
Topics: Androstadienes; Butadienes; Chromones; Enzyme Inhibitors; Female; Fibronectins; Flavonoids; Humans; | 2000 |
Cross-talk between signalling pathways and the multidrug resistant protein MDR-1.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Female; Flavonoi | 2001 |
Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells.
Topics: Cell Division; Cells, Cultured; Cyclic AMP; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibito | 2002 |